Bioliberty, stroke rehab goes home
Recovering a hand after a stroke does not stop when a patient leaves the rehabilitation facility. That is the case Bioliberty is now raising money on: its robotic therapy was co-developed with inpatient rehabilitation facilities, and the next setting is the home.
The company is based in Edinburgh and Boston. It emerged from the School of Engineering at The University of Edinburgh, where two of its four co-founders, Rowan Armstrong and Ross O'Hanlon, studied. Edinburgh Innovations supported the founding, and the university's venture fund Old College Capital has backed the company from the start.
On 6 November, EU-Startups reported that Bioliberty has raised a Series A extension of €2.95 million, about $3.3 million. The new investors are TGH Ventures, the investment arm of Tampa General Hospital, plus Ballad Ventures, 25m Health and Belfast-based Whiterock. It follows a £7.7 million Series A announced in March, led with £3 million by The Scottish National Investment Bank.
The product is a three-part system. Lifeglov is an air-powered soft robotic glove that helps patients open and strengthen their hands. Lifehub is the portable unit that runs the therapy sessions. Lifemind is a clinician dashboard that tracks progress and uses AI to draft clinical notes. According to the company, Lifehub and Lifeglov are FDA-listed, and it launched commercially in the US in 2025.
What the money pays for: extending the technology into the home, connecting rehabilitation data across care settings, and building AI tools for clinical decisions. CEO Rowan Armstrong calls the funding and new investors "crucial to our next phase: creating a more connected rehabilitation journey."